These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8695242)

  • 1. An economic model to assess the savings from a clinical application of haematopoietic growth factors.
    Uyl-de Groot CA; Vellenga E; Rutten FF
    Eur J Cancer; 1996 Jan; 32A(1):57-62. PubMed ID: 8695242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.
    Lyman GH; Lyman CG; Sanderson RA; Balducci L
    J Natl Cancer Inst; 1993 Mar; 85(6):488-93. PubMed ID: 8445677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
    Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
    Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic factors for febrile neutropenia].
    Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
    Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?
    Hackshaw A; Sweetenham J; Knight A
    Br J Cancer; 2004 Apr; 90(7):1302-5. PubMed ID: 15054445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
    Lyman GH; Kuderer NM
    Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
    J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost implications of haematopoietic growth factors in the BMT setting.
    Petros WP; Peters WP
    Bone Marrow Transplant; 1993; 11 Suppl 2():36-8. PubMed ID: 8334436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
    Cosler LE; Eldar-Lissai A; Culakova E; Kuderer NM; Dale D; Crawford J; Lyman GH
    Pharmacoeconomics; 2007; 25(4):343-51. PubMed ID: 17402806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations.
    de Lalla F
    Drugs; 1997 May; 53(5):789-804. PubMed ID: 9129866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic evaluation of the use of haematopoietic factors in managing malignant hemopathies].
    Durand-Zaleski I; Chaix C
    Rev Med Interne; 1997; 18(8):662-7. PubMed ID: 9365743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia.
    Bash RO; Katz JA; Cash JV; Buchanan GR
    Cancer; 1994 Jul; 74(1):189-96. PubMed ID: 8004575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of new treatments: haematopoietic growth factors.
    Johnson NJ; Rees GJ
    Clin Oncol (R Coll Radiol); 1996; 8(1):43-7. PubMed ID: 8688361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.
    Rofail P; Tadros M; Ywakim R; Tadrous M; Krug A; Cosler LE
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):699-709. PubMed ID: 23252353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.
    Lyman GH
    Eur J Cancer; 2000 Apr; 36 Suppl 1():S15-21. PubMed ID: 10785605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.
    Oude Nijhuis C; Kamps WA; Daenen SM; Gietema JA; van der Graaf WT; Groen HJ; Vellenga E; Ten Vergert EM; Vermeulen KM; de Vries-Hospers HG; de Bont ES
    J Clin Oncol; 2005 Oct; 23(30):7437-44. PubMed ID: 16234511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.